Literature DB >> 31183846

Potential Involvement of Osteopontin in Inflammatory and Fibrotic Processes in Pulmonary Embolism and Chronic Thromboembolic Pulmonary Hypertension.

Sebastian Kölmel1, Lukas Hobohm1,2, Anja Käberich1,2, Valentin J Krieg1, Magdalena L Bochenek1,2,3, Philip Wenzel1,2,3, Christoph B Wiedenroth4, Christoph Liebetrau3,5,6, Gerd Hasenfuß7,8, Eckhard Mayer4, Stavros V Konstantinides1,9, Katrin Schäfer2,3, Stefan Guth4, Mareike Lankeit1,7,10,11.   

Abstract

BACKGROUND: Inflammation and incomplete thrombus resolution leading to obstructive fibrotic remodelling are considered critical mechanisms for the development of chronic thromboembolic pulmonary hypertension (CTEPH) after pulmonary embolism (PE). Osteopontin (OPN) is involved in a variety of biological processes including inflammation and tissue fibrosis.
METHODS: OPN plasma concentrations were measured in 70 CTEPH and 119 PE patients. Tissue material from 6 CTEPH patients removed during pulmonary endarterectomy and murine venous thrombi induced by subtotal ligation of the inferior vena cava in C57BL/6 mice were analysed by (immuno)histochemistry.
RESULTS: CTEPH patients had higher OPN plasma concentrations (median, 106.9 [interquartile range, 75.6-155.9]) compared to PE patients (90.4 [53.3-123.9] ng/mL, p = 0.001). OPN- and matrix metalloproteinase (MMP)-9-positive cells were predominantly present in myofibroblast-rich and profibrotic areas of CTEPH tissue material. Early stages of murine thrombus resolution were characterised by high numbers of OPN- and MMP-2-positive cells while OPN was almost absent in fresh thrombi of CTEPH tissue material. PE patients with OPN plasma concentrations of < 55 ng/mL had a 15.2-fold (95% confidence interval, 1.7-135.5, p = 0.015) increased risk for a diagnosis of CTEPH during follow-up.
CONCLUSION: The results of the present observational translational study point to a possible involvement of OPN in the pathogenesis of CTEPH by affecting early inflammatory and late fibrotic processes. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31183846     DOI: 10.1055/s-0039-1692174

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  4 in total

1.  Model of Chronic Thromboembolic Pulmonary Hypertension in Rats Caused by Repeated Intravenous Administration of Partially Biodegradable Sodium Alginate Microspheres.

Authors:  Andrei A Karpov; Nikita A Anikin; Aleksandra M Mihailova; Sergey S Smirnov; Dariya D Vaulina; Leonid A Shilenko; Dmitry Yu Ivkin; Alexei Y Bagrov; Olga M Moiseeva; Michael M Galagudza
Journal:  Int J Mol Sci       Date:  2021-01-24       Impact factor: 5.923

2.  Role of Osteopontin as a Potential Biomarker of Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis and Other Connective Tissue Diseases (CTDs).

Authors:  Mattia Bellan; Cristina Piccinino; Stelvio Tonello; Rosalba Minisini; Ailia Giubertoni; Daniele Sola; Roberta Pedrazzoli; Ileana Gagliardi; Erika Zecca; Elisa Calzaducca; Federica Mazzoleni; Roberto Piffero; Giuseppe Patti; Mario Pirisi; Pier Paolo Sainaghi
Journal:  Pharmaceuticals (Basel)       Date:  2021-04-21

Review 3.  An Overview of Circulating Pulmonary Arterial Hypertension Biomarkers.

Authors:  Joana Santos-Gomes; Inês Gandra; Rui Adão; Frédéric Perros; Carmen Brás-Silva
Journal:  Front Cardiovasc Med       Date:  2022-07-14

4.  Extracellular matrix collagen biomarkers levels in patients with chronic thromboembolic pulmonary hypertension.

Authors:  Wenyi Pang; Zhu Zhang; Yunxia Zhang; Meng Zhang; Ran Miao; Yuanhua Yang; Wanmu Xie; Jun Wan; Zhenguo Zhai; Chen Wang
Journal:  J Thromb Thrombolysis       Date:  2020-11-11       Impact factor: 2.300

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.